Bolt Biotherapeutics, Inc. (BOLT)

Bolt Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	11.7	7.21	10.81	9.24	27.38
Short-Term Investments	15.8	40.12	91.38	159.64	158.84
Cash & Short-Term Investments	27.51	47.32	102.19	168.89	186.22
Cash Growth	-41.88%	-53.69%	-39.49%	-9.31%	715.39%
Other Current Assets	2.76	3.49	3.52	3.86	2.94
Total Current Assets	30.26	50.81	105.71	172.75	189.16
Net Property, Plant & Equipment	20.48	24.9	24.08	28.53	30.6
Long-Term Investments	4.34	22.88	26.41	23.94	85.35
Other Long-Term Assets	1.68	1.04	3.59	2.59	2.61
Total Assets	56.75	99.63	159.78	227.81	307.72
Accounts Payable	1.44	1.51	2.99	3.59	3.57
Accrued Expenses	3.72	9.08	12.49	15.14	12.38
Current Portion of Leases	2.83	2.25	2.78	2.39	2.5
Unearned Revenue	0.45	3.02	2.2	1.99	2.87
Total Current Liabilities	8.44	15.86	20.46	23.12	21.33
Long-Term Leases	20.13	22.96	17.44	20.22	21.85
Other Long-Term Liabilities	1.68	3.62	9.15	12.96	14.42
Total Long-Term Liabilities	21.81	26.58	26.59	33.18	36.27
Total Liabilities	30.24	42.43	47.04	56.3	57.6
Additional Paid-in Capital	487.31	484.5	476.99	467.51	457.43
Accumulated Other Comprehensive Income	-0.02	0.1	0.04	-0.92	-0.32
Retained Earnings	-460.78	-427.4	-364.29	-295.09	-206.99
Total Common Shareholders' Equity	26.51	57.2	112.74	171.51	250.12
Shareholders' Equity	26.51	57.2	112.74	171.51	250.12
Total Liabilities & Equity	56.75	99.63	159.78	227.81	307.72
Total Debt	22.96	25.21	20.22	22.61	24.36
Net Cash (Debt)	4.55	22.11	81.97	146.28	161.86
Net Cash Growth	-79.44%	-73.02%	-43.96%	-9.63%	1253.27%
Net Cash Per Share	2.43	11.58	43.36	78.31	97.52
Book Value	26.51	57.2	112.74	171.51	250.12
Book Value Per Share	14.17	29.96	59.63	91.82	150.69
Tangible Book Value	26.51	57.2	112.74	171.51	250.12
Tangible Book Value Per Share	14.17	29.96	59.63	91.82	150.69

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q